107 related articles for article (PubMed ID: 17928366)
41. Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation.
Houde N; Beuret L; Bonaud A; Fortier-Beaulieu SP; Truchon-Landry K; Aoidi R; Pic É; Alouche N; Rondeau V; Schlecht-Louf G; Balabanian K; Espéli M; Charron J
Cell Rep; 2022 Jan; 38(2):110223. PubMed ID: 35021072
[TBL] [Abstract][Full Text] [Related]
42. The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation.
Grasso M; Bond GJ; Kim YJ; Boyd S; Matson Dzebo M; Valenzuela S; Tsang T; Schibrowsky NA; Alwan KB; Blackburn NJ; Burslem GM; Wittung-Stafshede P; Winkler DD; Marmorstein R; Brady DC
J Biol Chem; 2021 Dec; 297(6):101314. PubMed ID: 34715128
[TBL] [Abstract][Full Text] [Related]
43. Identification of a C-terminal region that is required for the nuclear translocation of ERK2 by passive diffusion.
Shibayama S; Shibata-Seita R; Miura K; Kirino Y; Takishima K
J Biol Chem; 2002 Oct; 277(40):37777-82. PubMed ID: 12149268
[TBL] [Abstract][Full Text] [Related]
44. Mitogen-activated protein kinase (MAPK) pathway regulates branching by remodeling epithelial cell adhesion.
Ihermann-Hella A; Lume M; Miinalainen IJ; Pirttiniemi A; Gui Y; Peränen J; Charron J; Saarma M; Costantini F; Kuure S
PLoS Genet; 2014 Mar; 10(3):e1004193. PubMed ID: 24603431
[TBL] [Abstract][Full Text] [Related]
45. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas.
Murugan AK; Dong J; Xie J; Xing M
Cell Cycle; 2009 Jul; 8(13):2122-4. PubMed ID: 19411838
[TBL] [Abstract][Full Text] [Related]
46. Monomeric and dimeric models of ERK2 in conjunction with studies on cellular localization, nuclear translocation, and in vitro analysis.
Lee S; Bae YS
Mol Cells; 2012 Apr; 33(4):325-34. PubMed ID: 22450690
[TBL] [Abstract][Full Text] [Related]
47. Towards the development of chromone-based MEK1/2 modulators.
Redwan IN; Dyrager C; Solano C; Fernández de Trocóniz G; Voisin L; Bliman D; Meloche S; Grøtli M
Eur J Med Chem; 2014 Oct; 85():127-38. PubMed ID: 25078316
[TBL] [Abstract][Full Text] [Related]
48.
Beuret L; Fortier-Beaulieu SP; Rondeau V; Roy S; Houde N; Balabanian K; Espéli M; Charron J
Front Cell Dev Biol; 2021; 9():639022. PubMed ID: 34386488
[TBL] [Abstract][Full Text] [Related]
49. Mutations in ERK2 binding sites affect nuclear entry.
Yazicioglu MN; Goad DL; Ranganathan A; Whitehurst AW; Goldsmith EJ; Cobb MH
J Biol Chem; 2007 Sep; 282(39):28759-28767. PubMed ID: 17656361
[TBL] [Abstract][Full Text] [Related]
50. Expression and purification of phosphorylated and non-phosphorylated human MEK1.
Smith CK; Carr D; Mayhood TW; Jin W; Gray K; Windsor WT
Protein Expr Purif; 2007 Apr; 52(2):446-56. PubMed ID: 17175166
[TBL] [Abstract][Full Text] [Related]
51. ERK2 Mutations Affect Interactions, Localization, and Dimerization.
Taylor CA; Cormier KW; Martin-Vega A; Earnest S; Stippec S; Wichaidit C; Cobb MH
Biochemistry; 2023 May; 62(9):1433-1442. PubMed ID: 37021821
[TBL] [Abstract][Full Text] [Related]
52. The nuclear localization of ERK2 occurs by mechanisms both independent of and dependent on energy.
Ranganathan A; Yazicioglu MN; Cobb MH
J Biol Chem; 2006 Jun; 281(23):15645-52. PubMed ID: 16595679
[TBL] [Abstract][Full Text] [Related]
53. Asleep at the switch: MEK kinases control transit to gliogenesis in developing cortex.
Zhou J; Stiles CD
Neuron; 2012 Sep; 75(6):940-2. PubMed ID: 22998861
[TBL] [Abstract][Full Text] [Related]
54. Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.
Chen T; Yang M; Yu Z; Tang S; Wang C; Zhu X; Guo J; Li N; Zhang W; Hou J; Liu H; Han C; Liu Q; Gu Y; Qian C; Wan T; Cui L; Zhu M; Zheng W; Cao X
Cancer Cell; 2021 Mar; 39(3):438-440. PubMed ID: 33689704
[No Abstract] [Full Text] [Related]
55. Macrocyclic Inhibitors of ERK2 Kinase.
Rosse G
ACS Med Chem Lett; 2016 Dec; 7(12):1020-1021. PubMed ID: 27994729
[No Abstract] [Full Text] [Related]
56. Correction: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.
Clin Cancer Res; 2016 Nov; 22(22):5619. PubMed ID: 28151716
[No Abstract] [Full Text] [Related]
57. ERK2 Inhibitors May Provide Treatment for Cancer.
Abdel-Magid AF
ACS Med Chem Lett; 2013 Jul; 4(7):576-7. PubMed ID: 24900713
[No Abstract] [Full Text] [Related]
58. "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.
Cseh B; Doma E; Baccarini M
FEBS Lett; 2014 Aug; 588(15):2398-406. PubMed ID: 24937142
[TBL] [Abstract][Full Text] [Related]
59. MEK1/2 dual-specificity protein kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2012 Jan; 417(1):5-10. PubMed ID: 22177953
[TBL] [Abstract][Full Text] [Related]
60. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M
Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
